Defining the need for new antimicrobials: Clinical and economic implications of resistance in the hospitalised patient

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 6, 2005, Pages 873-889

  DeRyke, C Andrew ^a   Maglio, Dana ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Antimicrobials; Gram negative; Gram positive; Multi drug resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; GATIFLOXACIN; GEMIFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; MEROPENEM; METICILLIN; MIKAMYCIN B; MINOCYCLINE; MOXIFLOXACIN; ORITAVANCIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TELAVANCIN; TIGECYCLINE; TIMENTIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST OF ILLNESS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; ENZYME SYNTHESIS; HEALTH CARE NEED; HEALTH ECONOMICS; HOSPITAL COST; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; NONHUMAN; OTITIS MEDIA; OUTCOMES RESEARCH; PHARMACODYNAMICS; PROCESS OPTIMIZATION; PSEUDOMONAS AERUGINOSA; REVIEW; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS;

EID: 21744450138     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.6.873     Document Type: Review

References (112)

1. COSGROVE SE, CARMELI Y: The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. (2003) 36:1433-1437.
2. PHELPS CE: Bug/drug resistance. Sometimes less is more. Med. Care. (1989) 27:194-203.
3. Impacts of antibiotic-resistant bacteria: thanks to penicillin - he will come home! Washington, DC: Office of technology assessment, Congress (1995). Publication OTA-H-629.
4. BARTLETT JG, DOWELL SF, MANDELL LA, FILE TM JR, MUSHER DM, FINE MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 31:347-382.
5. KUTI JL, CAPITANO B, NICOLAU DP: Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics (2002) 20:513-528.
6. DOERN GV: Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin. Infect. Dis. (2001) 33(Suppl. 3):S187-S192.
7. SPIKA JS, FACKLAM RR, PLIKAYTIS BD, OXTOBY MJ: Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J. Infect. Dis. (1991) 163:1273-1278.
8. JORGENSEN JH, DOERN GV, MAHER LA, HOWELL AW, REDDING JS: Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. (1990) 34:2075-2080
9. KARLOWSKY JA, THORNSBERRY C, JONES ME, EVANGELISTA AT, CRITCHLEY IA, SAHM DF; TRUST Surveillance Program: Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin. Infect. Dis. (2003) 36:963-970.
10. MANDELL LA, BARTLETT JG, DOWELL SF, FILE TM JR, MUSHER DM, WHITNEY C; Infectious Diseases Society of America: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. (2003) 37:1405-1433.
11. CLINICAL AND LABORATORY STANDARDS INSTITUTE/NCCLS: Methods for dilution antimicrobial susceptibilities tests for bacteria that grow aerobically - Fifteenth Informational Supplement. CLSI/NCCLS document M100-S15 (2005)
12. HEFFELFINGER JD, DOWELL SF, JORGENSEN JH et al.: Management of community-acquired pneumonia in the eral of pneumococcal resistance: a report for the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch. Intern. Med. (2000) 160:1399-1408.
13. LYNCH JP III, MARTINEZ FJ: Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin. Infect. Dis. (2002) 34(Suppl. 1):S27-S46.
14. GORDON KA, BIEDENBACH DJ, JONES RN: Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. (2003) 46:285-289.
15. AMBROSE PG, GRASELA DM, GRASELA TH, PASSARELL J, MAYER HB, PIERCE PF: Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. (2001) 45:2793-2797.
16. LOW DE: Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin. Infect. Dis. (2004) 38(Suppl. 4):S357-S362.
17. ANDERSON KB, TAN JS, FILE TM JR, DIPERSIO JR, WILLEY BM, LOW DE: Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin. Infect. Dis. (2003) 37:376-381.
18. DAVIDSON R, CAVALCANTI R, BRUNTON JL et al.: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. (2002) 346:747-750.
19. CHAN DK, MCGEER A, DEAZAVEDO JC et al.: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. (1999) 341:233-239.
20. NEUHAUSER MM, WEINSTEIN RA, RYDMAN R, DANZIGER LH, KARAM G, QUINN JP: Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA (2003) 289:885-888.
21. BISHAI W: The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J. Antimicrob. Chemother. (2002) 49:433-436.
22. YU VL, CHIOU CC, FELDMAN C et al.: International Pneumococcal Study Group: An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. (2003) 37:230-237.
23. LONKS JR, GARAU J, GOMEZ L et al.: Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. (2002) 35: 556-564.
24. NUERMBERGER E, BISHAI WR: The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Clin. Infect. Dis. (2004) 38:99-103.
25. HO PL, TSE WS, TSANG KW et al.: Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin. Infect. Dis. (2001) 32:701-707.
26. ZHANEL G, WALKTY A, NICHOL K, SMITH H, NOREDDIN A, HOBAN D: Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn. Microbiol. Infect. Dis. (2003) 45:63-67.
27. IANNINI PB, PALADINO JA, ADELMAN MH, FORREST A, SCHENTAG JJ: Macrolide failure in Streptococcus pneumoniae infections is an identifiable clinical event. [Abstract LB-6]. Infectious Diseases Society of America 2004 Annual Meeting. Boston, MA, USA September 30 - Ocotber 3 (2004).
28. CRAIG WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. (1998) 26:1-10.
29. KLEPSER ME, KLEPSER DG, ERNST EJ et al.: Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae. Pharmacotherapy (2003) 23:349-359.
30. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control. (2003) 31:481-498.
31. FRIDKIN SK, GAYNES RP: Antimicrobial resistance in intensive care units. Clin. Chest Med. (1999) 20:303-316.
32. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001. Am. J. Infect. Control (2001) 29:404-421.
33. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am. J. Infect. Control (2000) 28:429-448.
34. ENRIGHT MC, ROBINSON DA, RANDLE G, FEIL EJ, GRUNDMANN H, SPRATT BG: The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc. Natl. Acad. Sci. USA (2002) 99:7687-7692.
35. CENTERS FOR DISEASE CONTROL AND PREVENTION: Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb. Mortal. Wkly. Rep. (1997) 46:624-626.
36. CENTERS FOR DISEASE CONTROL AND PREVENTION: Reduced susceptibility of Staphylococcus aureus to vancomycin - United States, 2002. MMWR Morb. Mortal. Wkly. Rep. (2002) 51:565-567.
37. CENTERS FOR DISEASE CONTROL AND PREVENTION: Public Health Dispatch: Vancomycin -resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb. Mortal. Wkly. Rep. (2002) 51:902.
38. CENTERS FOR DISEASE CONTROL AND PREVENTION: Public Health Dispatch: Vancomycin -resistant Staphylococcus aureus - New York, 2002. MMWR Morb. Mortal. Wkly. Rep. (2004) 53:322-323.
39. AKINS RL, HAAS KK: Gram-positive resistance: pathogens, implications, and treatment options. Society of Infectious Disease Pharmacists newsletter (2004) 14:2-7.
40. TENOVER FC, WEIGEL LM, APPELBAUM PC et al.: Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. (2004) 48:275-280.
41. CENTERS FOR DISEASE CONTROL AND PREVENTION: Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR Morb. Mortal. Wkly. Rep. (1999) 48:707-710.
42. SALGADO CD, FARR BM, CALFEE DP: Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin. Infect. Dis. (2003) 36:131-139.
43. RYBAK MJ, TEDESCO KL, AMJAD M, MOBARAK R, KAATZ GW: Identification of community-associated methicillin-resistant Staphylococcus aureus (CAM RSA) by clinical and molecular methods in a large urban medical center in Detroit, MI. [Abstract C2-2006]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy,. Washington, DC, USA October 30 - November 2 (2004).
44. MARKOWITZ N, QUINN EL, SARAVOLATZ LD: Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med. (1992) 117:390-398.
45. PANAGEA S, PERRY JD, GOULD FK: Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci? J. Antimicrob. Chemother. (1999) 44:581-582.
46. DRINKOVIC D, FULLER FR, SHORE KP, HOLLAND DJ, ELLIS-PEGLER R: Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J. Antimicrob. Chemother. (2001) 48:315-316.
47. ROBERTS MC, SUTCLIFFE J, COURVALIN P, JENSEN LB, ROOD J, SEPPALA H: Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother. (1999) 43:2823-2830.
48. BLOT SI, VANDEWOUDE KH, HOSTE EA, COLARDYN FA: Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch. Intern. Med. (2002) 162:2229-2235.
49. RELLO J, TORRES A, RICART M et al.: Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am. J. Respir. Crit. Care Med. (1994) 150 (6 Pt 1):1545-1549.
50. COSGROVE SE, SAKOULAS G, PERENCEVICH EN, SCHWABER MJ, KARCHMER AW, CARMELI Y: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. (2003) 36:53-9.
51. SORIANO A, MARTINEZ JA, MENSA J et al.: Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin. Infect. Dis. (2000) 30:368-373.
52. COMBES A, LUYT CE, FAGON JY et al.; PNEUMA Trial Group: Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. (2004) 170:786-792.
53. GONZALEZ C, RUBIO M, ROMERO-VIVAS J, GONZALEZ M, PICAZO JJ: Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin. Infect. Dis. (1999) 29:1171-1177.
54. SANDIUMENGE A, DIAZ E, BODI M, RELLO J: Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of 'The Tarragona Strategy'. Intensive Care Med. (2003) 29:876-883.
55. WUNDERINK RG, RELLO J, CAMMARATA SK, CROOS-DABRERA RV, KOLLEF MH: Linezolid versus vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 124:1789-1797.
56. KOLLEF MH, RELLO J, CAMMARATA SK, CROOS-DABRERA RV, WUNDERINK RG: Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. (2004) 30:388-394
57. FAGON J, PATRICK H, HAAS DW et al.: Treatment of Gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial pneumonia Group. Am. J. Respir. Crit. Care Med. (2000) 161(3 Pt 1):753-762.
58. TAYLOR MD, NAPOLITANO LM: Methicillin-resistant Staphylococcus aureus infections in vascular surgery: increasing prevalence. Surg. Infect. (2004) 5:180-187.
59. ENGEMANN JJ, CARMELI Y, COSGROVE SE et al.: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. (2003) 36:592-598.
60. LECLERCQ R, DERLOT E, DUVAL J, COURVALIN P: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. (1988) 319:157-161.
61. JONES RN, PFALLER MA: Bacterial resistance: a worldwide problem. Diagn. Microbiol. Infect Dis. (1998) 31:379-388.
62. BHAVNANI SM, DRAKE JA, FORREST A et al.: A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn. Microbiol. Infect. Dis. (2000) 36:145-158.
63. LUCAS GM, LECHTZIN N, PURYEAR DW, YAU LL, FLEXNER CW, MOORE RD: Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin. Infect. Dis. (1998) 26:1127-1133.
64. STOSOR V, PETERSON LR, POSTELNICK M, NOSKIN GA: Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch. Intern. Med. (1998) 158:522-527.
65. LODISE TP, MCKINNON PS, TAM VH, RYBAK MJ: Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin. Infect. Dis. (2002) 34:922-929.
66. VERGIS EN, HAYDEN MK, CHOW JW et al.: Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia, a prospective multicenter study. Ann. Intern. Med. (2001) 135:484-492.
67. CARMELI Y, ELIOPOULOS G, MOZAFFARI E, SAMORE M: Health and economic outcomes of vancomycin-resistant enterococci. Arch. Intern. Med. (2002) 162:2223-2228.
68. WONG-BERINGER A: Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy (2001) 21:583-592.
69. KNOTHE H, SHAH P, KRCMERY V, ANTAL M, MITSUHASHI S: transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection (1983) 11:315-317.
70. LAUTENBACH E, PATEL JB, BILKER WB, EDELSTEIN PH, FISHMAN NO: Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. (2001) 32:1162-1171.
71. JONES RN, PFALLER MA, DOERN GV, ERWIN ME, HOLLIS RJ: Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn. Microbiol. Infect. Dis. (1998) 30:215-228.
72. DANDEKAR PK, QUINTILIANI R, NIGHTINGALE CH, NICOLAU DP: Extended-spectrum beta-lactamases (ESBL). Conn. Med. (2002) 66:13-15.
73. GO ES, URBAN C, BURNS J et al.: Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet (1994) 344:1329-1332.
74. RAHAL JJ, URBAN C, HORN D et al.: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. (1998) 280:1233-1237.
75. ONG CT, KUTI JL, NIGHTINGALE CH, NICOLAU DP: Emerging Pseudomonas aeruginosa resistance: implications in clinical practice. Conn. Med. (2004) 68:11-15.
76. PATERSON DL, KO WC, VON GOTTBERG A et al.: Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin. Infect. Dis. (2004) 39:31-37.
77. KANG CI, KIM SH, PARK WB et al.: Bloodstream infections due to extended-spectrum {beta}-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. (2004) 48:4574-4581.
78. LIVERMORE DM: Beta-lactamase-mediated resistance and opportunities for its control. J. Antimicrob. Chemother. (1998) 41 (Suppl. D):25-41.
79. CHOW JW, FINE MJ, SHLAES DM et al.: Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. (1991) 115:585-590.
80. KANG CI, KIM SH, PARK WB et al.: Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin. Infect. Dis. (2004) 39:812-818.
81. COSGROVE SE, KAYE KS, ELIOPOULOUS GM, CARMELI Y: Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med. (2002) 162:185-190.
82. KANG CI, KIM SH, KIM HB et al.: Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. (2003) 37:745-751.
83. LIVERMORE DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. (2002) 34:634-640.
84. ZERVOS MJ, HERSHBERGER E, NICOLAU DP et al.: Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin. Infect. Dis. (2003) 37:1643-1648.
85. POLK RE, JOHNSON CK, MCCLISH D et al.: Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin. Infect. Dis. (2004) 39:497-503.
86. BLOT S, VANDEWOUDE K, DE BACQUER D, COLARDYN F: Nosocomial bacteremia caused by antibiotic-resistant Gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin. Infect. Dis. (2002) 34:1600-1606.
87. CARMELI Y, TROILLET N, KARCHMER AW, SAMORE MH: Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch. Intern. Med. (1999) 159:1127-1132.
88. KOLLEF MH, SHERMAN G, WARD S, FRASER VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest (1999) 115:462-474.
89. IBRAHIM EH, SHERMAN G, WARD S, FRASER VJ, KOLLEF MH: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest (2000) 118:146-155.
90. KOLLEF MH: Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis. (2000) 31(Suppl. 4):S131-S138.
91. LODISE TP, MCKINNON PS, SWIDERSKI L, RYBAK MJ: Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. (2003) 36:1418-1423.
92. KANG CI, KIM SH, KIM HB et al.: Pseudomonas aerugnosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. (2003) 37:745-751.
93. LUNA CM, VUJACICH P, NIEDERMAN MS et al.: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest (1997) 111:676-685.
94. RELLO J, GALLEGO M, MARISCAL D, SONORA R, VALLES J: The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. (1997) 156:196-200.
95. ALVAREZ-LERMA F: Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. (1996) 22:387-394.
96. KOLLEF MH, WARD S: The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest (1998) 113:412-420.
97. KORZENIOWSKI O, SANDE MA: Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann. Intern. Med. (1982) 97:496-503.
98. CHAMBERS HF, MILLER RT, NEWMAN MD: Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann. Intern. Med. (1988) 109:619-624.
99. HILF M, YU VL, SHARP J, ZURAVLEFF JJ, KORVICK JA, MUDER RR: Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am. J. Med. (1989) 87:540-546.
100. BODEY GP, JADEJA L, ELTING L: Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch. Intern. Med. (1985) 145:1621-1629.
101. LEIBOVICI L, PAUL M, POZNANSKI O et al.: Monotherapy versus beta-lactamaminoglycoside combination treatment for Gram-negative bacteremia: a prospective, observational study. Antimicrob. Agents Chemother. (1997) 41:1127-1133.
102. PAUL M, BENURI-SILBIGER I, SOARES-WEISER K et al.: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Br. Med. J. (2004) 328:668.
103. PAUL M, SOARES-WEISER K, LEIBOVICI L: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br. Med. J. (2003) 326:11 11.
104. DENNESEN PJ, VAN DER VEN AJ, KESSELS AG, RAMSAY G, BONTEN MJ: Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. (2001) 163:1371-1375.
105. SINGH N, ROGERS P, ATWOOD CW, WAGENER MM, YU VL: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am. J. Respir. Crit. Care Med. (2000) 162(2 Pt 1):505-511.
106. IBRAHIM EH, WARD S, SHERMAN G, SCHAIFF R, FRASER VJ, KOLLEF MH: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit. Care Med. (2001) 29:1109-1115.
107. CHASTRE J, WOLFF M, FAGON JY et al.: Pneumonia Trial Group: Comparison of 8 versus 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA (2003) 290:2588-2598.
108. PATERSON DL: 'Collateral damage' from cephalosporin or quinolone antibiotic therapy. Clin. Infect Dis. (2004) 38(Suppl. 4):S341-S345.
109. GUAY DR: Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy (2004) 24:58-68.
110. ROBERTS MC: Tetracycline therapy: an update. Clin. Infect Dis. (2003) 36:462-467.
111. POSTIER RG, GREEN SL, KLEIN SR et al.: Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. (2004) 26:704-714.
112. MURRAY J, WILSON S, KLEIN S et al.: The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a Phase II clinical trial. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA. Sept 14 - 17 (2003).